Loss of cell division cycle 2 (Cdc2, also known as Cdk1) activity after cyclin B degradation is necessary, but not sufficient, for mitotic exit. Proteins phosphorylated by Cdc2 and downstream mitotic kinases must be dephosphorylated. We report here that protein phosphatase-1 (PP1) is the main catalyst of mitotic phosphoprotein dephosphorylation. Suppression of PP1 during early mitosis is maintained through dual inhibition by Cdc2 phosphorylation and the binding of inhibitor-1. Protein kinase A (PKA) phosphorylates inhibitor-1, mediating binding to PP1. As Cdc2 levels drop after cyclin B degradation, auto-dephosphorylation of PP1 at its Cdc2 phosphorylation site (Thr 320) allows partial PP1 activation. This promotes PP1-regulated dephosphorylation at the activating site of inhibitor-1 (Thr 35) followed by dissociation of the inhibitor-1-PP1 complex and then full PP1 activation to promote mitotic exit. Thus, Cdc2 both phosphorylates multiple mitotic substrates and inhibits their PP1-mediated dephosphorylation.
Exit from mitosis requires destruction of cyclin B, Cdc2 kinase inactivation and dephosphorylation of mitotic phosphoproteins. The identity and regulatory mechanisms of the vertebrate phosphatase(s) responsible for this dephosphorylation have not been established 1 
.
In yeast, dephosphorylation of mitotic phosphoproteins is catalysed by the phosphatase Cdc14. Before mitotic exit, Cdc14 is sequestered within the nucleolus through association with its inhibitor, nucleolar silencing establishing factor and telophase regulator (Net1). Cdc2-mediated Net1 phosphorylation promotes Cdc14 release from the nucleolus to allow dephosphorylation of mitotic phosphoproteins; nucleolar exclusion is then maintained by the mitotic exit network (MEN) [2] [3] [4] . Although Cdc14 homologues exist in vertebrates, they do not seem to have a similar role in these cells; however, yeast and vertebrate Cdc14 homologues share a conserved role in cytokinesis 5 .
In Aspergillus nidulans, Drosophila melanogaster and Schizosaccharomyces Pombe genetic analyses have suggested a role for PP1 in controlling mitotic exit [6] [7] [8] [9] . In interphase Xenopus egg extracts, it was reported that the predominant phosphatase that dephosphorylates phosphoproteins is neither PP1 nor protein phosphatase 2A (PP2A); however, the phosphatase functioning at mitotic exit may be different 10 . It has been reported that there is a requirement for okadaic acid-inhibitable phosphatase(s) in dephosphorylating Cdc2 substrates in human cells 11 and that calcineurin is required for the Ca 2+ -triggered mitotic exit in the cytostatic factor (CSF)-arrested egg 12, 13 . It has also been noted that additional unidentified phosphatase activity is required for full dephosphorylation of mitotic phosphoproteins and release from CSF arrest 12, 13 . From studying the early embryonic mitotic cycles in Xenopus, we have found that PP1 dephosphorylates mitotic phosphoproteins, as required for mitotic exit. However, we did not find a similar requirement for PP1 in exit from CSF arrest. Furthermore, we identified a regulatory loop that controls PP1 to promote the timely dephosphorylation of mitotic substrates. As reported previously, PP1 can be inhibited by Cdc2-mediated phosphorylation at Thr 320 14, 15 . We show that PP1 auto-dephosphorylates Thr 320, but that this activity is inhibited during M phase by the association of PP1 with inhibitor-1. Activation of inhibitor-1 through PKA-mediated phosphorylation of Thr 35 is enhanced in mitosis, both because PKA activity is elevated and because the rate of Thr 35 dephosphorylation is low. When cyclin B is destroyed at mitotic exit, the drop in Cdc2 activity allows the auto-dephosphorylation of PP1 to predominate, promoting its partial activation. PP1-regulated dephosphorylation of Thr 35 then inactivates inhibitor-1, allowing complete PP1 activation, dephosphorylation of mitotic phosphoproteins and mitotic exit.
Okadaic acid-inhibitable phosphatases are required for mitotic exit. To characterize the phosphatases involved in dephosphorylation of mitotic phosphoproteins, without having to account for possible effects of phosphatases in controlling the anaphase-promoting complex (APC) and cyclin degradation, we supplemented interphase egg extracts with recombinant, non-degradable cyclin B to drive mitotic entry, and then inhibited Cdc2 using the Cdc inhibitor roscovitine. This inhibition resulted in marked dephosphorylation of mitotic substrates, including the APC subunit Cdc27, and several mitotic phosphoproteins recognized by the mitotic protein monoclonal-2 (MPM-2) antibody (Fig. 1a) . The dephosphorylation was inhibited by okadaic acid, consistent with the involvement of PP1-or PP2A-like phosphatases (Fig. 1b) 11, 12 . Similar results were obtained when we treated CSF-arrested extracts with roscovitine ( Supplementary  Information, Fig. S1 ). Okadaic acid treatment did not affect Cdc2 kinase activity ( Fig. 1b; Supplementary Information, Fig. S1 ).
The phosphatase promoting mitotic exit was sensitive to 10 μM, but not 1 μM, okadaic acid (Fig. 1c, d ), consistent with the phosphatase being PP1-like, rather than PP2A-like 16 . We added a PP1-specific inhibitor (either inhibitor-1 or inhibitor-2) to roscovitine-treated extracts and monitored Cdc27-and MPM2-epitope dephosphorylation. Both inhibitor-1 and inhibitor-2 inhibited dephosphorylation of mitotic phosphoproteins (but not Cdc2 kinase activity; Fig. 2a, b) . We then immunodepleted PP1 from either mitotic or CSF-arrested meiotic extracts before adding roscovitine; we found that PP1 depletion prevented Cdc27 dephosphorylation in mitotic extracts and largely prevented dephosphorylation in the CSF-arrested extract, without affecting Cdc2 kinase activity (Fig. 2c, d ). The addition of recombinant PP1 to the depleted extract restored Cdc27 dephosphorylation (Fig. 2d) . Cdc27 exhibited partial dephosphorylation even in the presence of PP1-specific inhibitors or after PP1 depletion, reflecting either incomplete PP1 inhibition/depletion or the possible involvement of additional phosphatases.
Roscotivine ought to have mimicked the deactivation of Cdc2 after cyclin degradation. However, to confirm that PP1 was involved in the dephosphorylation of Cdc2 substrates after cyclin degradation, we added inhibitor-1 to cycling extracts of Xenopus eggs (that oscillate between S and M phase) immediately before mitosis; this largely prevented Cdc27 dephosphorylation (Fig. 2e) . The timing of inhibitor-1 addition was crucial because if added too early it could inhibit mitotic entry, perhaps reflecting the requirement for PP1 in promoting Cdc25 (a cell-cycle regulator) activation 17, 18 . To investigate further the physiological relevance of PP1-mediated mitotic substrate dephosphorylation, we examined the effect of PP1 inhibition in HeLa cell lysates. We found that cell lysates prepared from mitotically-arrested HeLa cells exited mitosis spontaneously as indicated by cyclin B degradation ( Supplementary Information, Fig. S2A ), and that both inhibitor-1 and inhibitor-2 largely prevented dephosphorylation of mitotic phosphoproteins ( Fig. 2f; Supplementary Information, Fig. S2B ). Cdc2 kinase assays confirmed that the delayed mitotic substrate dephosphorylation was due to PP1 inhibition and not sustained Cdc2 kinase activity. We did not examine mitotic exit after knockdown of PP1 in intact HeLa cells, as PP1 is required for mitotic entry 17 . Release from CSF arrest requires calcineurin to promote mitotic substrate dephosphorylation 12, 13 . Consistent with previous reports, Cdc27 dephosphorylation after Ca 2+ addition to CSF extracts was markedly delayed by the calcineurin inhibitor cyclosporine A ( Supplementary  Information, Fig. S2C ) 12, 13 . It has also been reported that an additional phosphatase cooperates with calcineurin to achieve full dephosphorylation of meiotic phosphoproteins 12, 13 . As neither inhibitor-1 addition nor PP1 depletion altered Cdc27 dephosphorylation after Ca 2+ addition to CSF-arrested extracts, PP1 is unlikely to be the additional phosphatase required for CSF release (Fig. 2g, h ). Taken together, the results indicate that PP1 is required for dephosphorylation of substrates at mitotic, but not meiotic, exit. Because PP1 seems to be required for dephosphorylation of M-phase phosphoproteins in the mitotic (but not meiotic) cycle, we thought excess PP1 might drive mitotic substrate dephosphorylation even in the absence of roscovitine. However, excess PP1 (added at levels 8-fold 
(g). Ca
2+ was added to CSF extracts in the presence of GST or GST-inhibitor-1. Aliquots were immunoblotted with an anti-Cdc27 antibody. (h) PP1 antibodies were used for PP1 immunodepletion and rabbit IgG was used for control depletion. Calcium was added to the depleted CSF extracts and aliquots were withdrawn at the indicated times and blotted with an antiCdc27 antibody (left). Aliquots of depleted extracts were also blotted with an anti-PP1 antibody (right).
greater than those found endogenously, 0.5 μM) did not drive Cdc27 dephosphorylation in mitotic (or meiotic) extracts (Fig. 3a) . The PP1 added was active and able to dephosphorylate Cdc25 at a known PP1 site ( Supplementary Information, Fig. S3 ). These data suggest that PP1 might be inactivated in M phase to prevent premature dephosphorylation of mitotic phosphoproteins. This is interesting as it has previously been suggested that Cdc2 activity could inhibit dephosphorylation of Cdc2/cyclin B substrates 11 . It is known that Cdc2 can inhibit PP1 and that phosphorylation of PP1 at Thr 320 peaks in mitosis in mammalian cells 14 . However, the physiological consequences of altering this phosphorylation have not been reported. Accordingly, we mutated Thr 320 to Ala, and added this recombinant PP1 to mitotic egg extracts. When added at levels 8-fold greater than that found endogenously, the mutant, but not wild-type, PP1 promoted Cdc27 dephosphorylation (Fig. 3b, c) , suggesting that PP1 inhibition by Cdc2 can be overcome by mutation of Thr 320. However, at lower levels (~2-4-fold greater then that found endogenously) this mutant protein alone was insufficient to drive dephosphorylation of Cdc2 substrates (Fig. 4k l) , raising the possibility that another cell-cycleregulated activity might control PP1.
Consistent with the idea that PP1-mediated dephosphorylation of mitotic phosphoproteins could be inhibited by Cdc2 phosphorylation of PP1 Thr 320, when we added roscovitine to mitotic egg extracts, Cdc27 dephosphorylation and PP1 Thr 320 dephosphorylation were coincident (Fig. 4a) . To determine how Thr 320 dephosphorylation might be regulated, we monitored PP1 Thr 320 phosphorylation throughout the cell cycle in a cycling extract. It was found that mitosis occurred at 80 min and interphase resumed at ~100 min (Fig. 4b) . Thr 320 of PP1 was noticeably dephosphorylated by 100 min, consistent with phosphorylation of this site inhibiting PP1 function ( Fig. 4b, left ; some interphase phosphorylation may have resulted from constitutively active Cdk2 in egg extracts). When these experiments were repeated and extracts were supplemented with inhibitor-1 immediately before mitotic entry, Thr 320 dephosphorylation was abrogated (Fig. 4b, right) , suggesting that PP1 might auto-dephosphorylate Thr 320. Indeed, PP1 was more robustly phosphorylated in vitro by recombinant Cdc2 when treated with inhibitor-2 (Fig. 4c) . More importantly, pre-phosphorylated purified PP1 was able to auto-dephosphorylate in vitro in the absence of any cofactors (Fig. 4d) .
We reasoned that if PP1 could auto-dephosphorylate to relieve its Cdc2-mediated inhibition, there must be an additional factor restraining PP1 activity during M phase. Specifically, as inhibitor-1 is controlled by phosphorylation, we speculated that cell-cycle regulation of inhibitor-1 phosphorylation might contribute to the control of mitotic exit 19 . PP1 phosphorylated at Thr 320 in CSF extracts could be co-immunoprecipitated with endogenous inhibitor-1 (Fig. 4e, f) . Moreover, mitotic PP1 exhibited much higher phosphorylation than interphase PP1 (Fig. 4g) . As in Xenopus egg extracts, inhibitor-1 interacted with PP1 in mitotic HeLa cell lysates (Fig. 4h) .
PKA phosphorylates inhibitor-1 and this phosphorylation is required for inhibitor-1 activity 20 . If inhibitor-1-mediated phosphorylation contributes to M phase restraint of PP1, activation of PKA should strengthen inhibitor-1-PP1 interactions. Accordingly, the PKA activator 8-bromo cyclic AMP (8br-cAMP) enhanced binding of PP1 to inhibitor-1 (Fig. 4i) . Moreover, wild-type inhibitor-1 bound more strongly to PP1 than the mutant inhibitor-1 T35A lacking the site of PKA phosphorylation; inhibitor-1 T35A binding was not enhanced by 8br-cAMP (Fig. 4i, j) . When CSF extracts were treated with the PKA-specific inhibitor PKI, the mutant PP1 T320A or both, PKI synergized with low levels of PP1 T320A (4-fold greater than endogenous levels), allowing dephosphorylation of Cdc2 substrates, even without roscovitine addition (Fig. 4k) . Moreover, Cdc2 substrate dephosphorylation correlated with inhibitor-1 dephosphorylation (Fig. 4l) . Thus, suppressing inhibitor-1 activation and preventing Cdc2-mediated PP1 inhibition could change the Cdc2/PP1 balance in favour of substrate dephosphorylation.
These results suggest that the phosphorylation and dephosphorylation of inhibitor-1 must be under cell-cycle control. To assess this, we first examined phosphorylation (p) of inhibitor-1. PP1 co-immunoprecipitated with inhibitor-1, as recognized by an anti-pThr 35 inhibitor-1 antibody (Fig. 5a) . PKA-mediated inhibitor-1 pThr 35 phosphorylation was, as reported, required for the PP1 inhibitory activity of inhibitor-1 (Fig. 5b) . Moreover, PKA immunoprecipitated from mitotic egg extracts or HeLa cell lysates phosphorylated inhibitor-1 much more robustly than PKA from interphase extracts or lysates (Fig. 5c ), consistent with a previous report that PKA activity peaks in mitosis 21 . Equal amounts of PKA were immunoprecipitated from interphase and mitotic extracts ( Supplementary Information, Fig. S4A ). In addition, inhibitor-1 lost significant activity when PKA was inhibited by PKI (Fig. 5d) . Conversely, thio-phosphorylated inhibitor-1 largely inhibited PP1 (and consequently Cdc27 dephosphorylation) even in the presence of PKI, indicating that inhibitor-1 is a key mitotic target of PKA in preventing dephosphorylation of M-phase substrates. We next sought to identify the inhibitor-1-directed phosphatase. Inhibitor-1, radiolabelled in the presence of [γ-32 P]ATP and PKA, was dephosphorylated in interphase, but not mitotic, egg extracts (Fig. 5e), suggesting that the inhibitor-1-directed phosphatase might be cell-cycle regulated (Thr 35 is the only PKA-phophorylated site on inhibitor-1; Supplementary Information, Fig. S4B ). When we treated CSF extracts with roscovitine, we detected inhibitor-1 dephosphorylation, suggesting that inhibitor-1 might be controlled by a Cdc2-inhibited phosphatase (Fig. 5f) . Importantly, inhibitor-1 dephosphorylation was inhibited in PP1-depleted extracts (Fig. 5g) . Similar results were obtained in CSF extracts supplemented with calcium (Fig. 5h) . Finally, PP1
T320A mutant addition (at levels 8-fold to endogenous PP1) dramatically promoted pre-phosphorylated as in e and then dipped in CSF extracts or CSF extracts pre-treated with DMSO or roscovitine and processed as in e. (g) GlutathioneSepharose-bound GST-inhibitor-1 was pre-phosphorylated as in e, dipped into IgG-(control) or PP1-depleted CSF extracts in the presence of roscovitine, and aliquots were processed as in e (left). Aliquots of IgG-or PP1-depleted extracts were immunoblotted for PP1 (Right). (h) IgG-or PP1-depleted CSF extracts were treated with Ca 2+ for 20 min. Glutathione-Sepharose-bound or pre-phosphorylated GST-inhibitor-1 was dipped into the Ca 2+ treated extracts as in e. Aliquots were resolved by SDS-PAGE/PhosphorImager (left). IgG-or PP1-depleted extracts were also immunoblotted for PP1 (right). (i) Glutathione-Sepharose-bound GST-inhibitor-1 pre-phosphorylated as in e was dipped into CSF extracts supplemented with XB buffer or His-PP1 T320A (4 μM), and processed as in e. Samples were also immunoblotted for Cdc27. (j) During mitosis PP1 is inhibited by Cdc2/ cyclin B and phosphorylated inhibitor-1. During mitotic exit, Cdc2 inactivation allows PP1 auto-dephosphorylation at Thr 320 and, at the same time, active PP1 dephosphorylates inhibitor-1 at Thr 35, resulting in the full activation of PP1.
inhibitor-1 dephosphorylation and this correlated directly with the gel mobility downshift of Cdc27 in SDS-PAGE (Fig. 5i) .
We show here that appropriately timed, PP1-mediated dephosphorylation of mitotic phosphoproteins, which is required for mitotic exit 11, 22 , results from the combined effects of Cdc2-mediated phosphorylation of PP1 Thr 320, auto-dephosphorylation of PP1 Thr 320 and PKAcontrolled inhibitor-1-PP1 binding (Fig. 5j) .
In that inhibitor-1 prevented dephosphorylation of PP1 in cycling extracts, and inhibitor-2 enhanced the weak in vitro phosphorylation of PP1 by Cdc2/cyclin B, it seems that PP1 catalytic activity is required for Thr 320 dephosphorylation. Indeed, pre-phosphorylated PP1 was dephosphorylated after incubation in the absence of any cofactor, substantiating the idea that PP1 can auto-dephosphorylate.
Although PP1 activity is inhibited during M phase to ensure accumulation of mitotic phosphoproteins, some PP1 activity is required for Cdc25 activation to promote mitotic entry 7 . After entry into mitosis, PP1 activity can be suppressed through Thr 320 phosphorylation and binding of inhibitor-1, which is enhanced by the M phase peak in PKA-mediated Thr 35 phosphorylation. Unlike in cardiac myocytes or renal medulla where inhibitor-1 dephosphorylation seems to be regulated by PP2A and calcineurin or PP2A (refs 23, 24) , respectively, in embryonic mitotic cycles inhibitor-1 dephosphorylation seems to be controlled by PP1. Although we have shown that PP1 is required for inhibitor-1 Thr 35 dephosphorylation, previous in vitro studies 20 indicate that PP1 may not directly dephosphorylate Thr 35 . In theory, PP1 may function through its ability to dephosphorylate other sites in inhibitor-1 that influence the phosphorylation/dephosphorylation of Thr 35, or PP1 may regulate another phosphatase to promote inhibitor-1 dephosphorylation 25 . Though exogenous inhibitor-2 could control PP1 in M-phase extracts, it is not known if inhibitor-2 is normally present in these extracts and/or if inhibitor-2 is also cell-cycle regulated. Inhibitor-2 does not require phosphorylation for activation and we did not see cell-cycle regulated oscillations in its stability or activity when exogenously added.
As cells enter mitosis, the phosphorylation of mitotic proteins is precisely timed and spatially regulated. The same is probably true for dephosphorylation of mitotic substrates by PP1, whose regulation by subcellular location remains to be determined. Proteins phosphorylated at mitosis by enzymes other than Cdc2 may be subject to distinct regulation, either by PP1 or other phosphatases.
Although targeting subunits of PP1 typically confer substrate recognition, substrate recognition can also occur through direct docking of PP1 (refs 18, 26) . It will be interesting to determine if recognition of mitotic phosphoproteins occurs through a uniform mechanism or if different substrates are recognized by different targeting subunits/direct docking. Since cell-cycle regulation of PP1 appears to be at the level of the catalytic subunit (through phosphorylation and inhibitor-1 binding), there may be no need to invoke targeting-subunit regulation to explain cell-cycledependent dephosphorylation of mitotic phosphoproteins.
We did not see any effect of PP1 depletion on Ca
2+
-induced release from CSF arrest. Therefore, PP1 is unlikely to be the phosphatase that cooperates with calcineurin at meiotic exit. Because okadaic acid can inhibit full dephosphorylation of meiotic phosphoproteins, and as PP1 and PP2A represent > 95% of the okadaic acid-sensitive phosphatase activity in egg extracts, PP2A may be involved.
Following PP1 depletion or inhibition, we still observed partial Cdc27 dephosphorylation at mitotic exit. Thus, it remains possible that additional phosphatases contribute to mitotic substrate dephosphorylation. In yeast, Cdc14 is the major phosphatase catalysing M-phase substrate dephosphorylation. Interestingly, negative feedback loops also link Cdc2 and Cdc14 (ref.27) . Even within the same species different phosphatases might be utilized under different circumstances. Moreover, more than one phosphatase may cooperate in substrate dephosphorylation at mitosis, either within a single cell type or in a manner dependent on cell type or developmental stage. Our analysis demonstrates that PP1 makes an important contribution to M-phase substrate dephosphorylation in vertebrate mitotic divisions and that a tightly regulated feedback loop ensures that dephosphorylation will occur in a timely manner, which is well-coordinated with the destruction of cyclin B.
METHODS
Cloning and protein expression. Xenopus PP1 cDNA was cloned from an oocyte cDNA library using the following primers: forward 5'-GCCGAATTCATGGGGGACGGAGAAAAACTAAA-3' and reverse 5'-GGCTCTAGATCATTTGGACTGTTTGTTTTTG-3' . It was then cloned into pMAL-c2× in frame with maltose-binding protein (MBP) or pGE×-KG in frame with glutathione S-transferase (GST). Rabbit His-PP1 was a gift from D. Armstrong (National Institute for Environmental Health Services, NC).
His-tagged proteins or GST-fusion proteins were expressed in bacteria and purified by using Ni-NTA agarose (Invitrogen) or glutathione-Sepharose beads (Amersham), respectively. All eluted proteins were dialysed into XB buffer (100 mM KCl, 50 mM sucrose, 10 mM Hepes at pH 7.7, 1 mM MgCl 2 , 0.1 mM CaCl 2 and 0.5 mM EGTA).
Antibodies. Rabbit polyclonal anti-×PP1 was raised against MBP-×PP1 protein and affinity purified using GST-xPP1. Anti-Cdc27 (BD Biosciences, 1:2,000), anti-MPM2 (Upstate, 1:2,000), anti-pCdc2 (Upstate, 1:2,000), anti-pPP1T320 (Abcam, 1:2,000), anti-cyclin B1 (Santa Cruz, 1:2,000), anti-PKA (Abcam, 1:2,000) and anti-pPlk1 (Abcam, 1:2,000) antibodies were used. Anti-cyclin B2 28 , anti-inhibitor-1 30 and anti-pinhibitor-1 31 antibodies were as reported previously.
Xenopus egg extracts and immunodepletion. Xenopus cycling extracts, interphase extracts and CSF extracts were prepared as described previously 29 . Mitotic extracts were prepared by adding non-degradable cyclin B1 to interphase extracts.
For immunodepletion of PP1, CSF or mitotic extracts were incubated with a purified polyclonal anti-×PP1 antibody coupled to protein A-Sepharose beads for 30 min at 4 °C. After incubation, the beads were removed and the supernatants underwent another two consecutive depletions. The same amount of control, rabbit IgG (Jackson Immuno Research), was used for mock depletion.
Tissue culture. HeLa cells were treated with nocodazole (40 ng ml -1 ) for 17 h for arrest in mitosis. Cells were then washed twice with PBS and cultured in fresh Dulbecco's modified Eagle's medium (DMEM) for 1 h. Finally, the cells were lysed in hypotonic buffer (20 mM HEPES at pH 7.5, 5 mM KCl, 1.5 mM MgCl2 and 1 mM dithiotheitol; DTT) using a Dounce homogenizer and cellular supernatants were collected after centrifugation for 15 min at 16,000g.
Dephosphorylation assays. To generate pre-phosphorylated GST-Cdc25 or GST-inhibitor-1, glutathione-Sepharose beads coupled with GST fusion proteins were incubated in kinase buffer (10 mM Tris-HCl at pH 7.2, 0.1 mM ATP, 2 μCi [γ-32 P]ATP, 10 mM MgCl 2 and 1 mM DTT at pH 7.2) with checkpoint kinase 1 (Chk1) or PKA (New England Biolabs) for 30 min at room temperature before washing. Glutathione-Sepharose beads bound to pre-phosphorylated proteins were then dipped into phosphatase buffer (10 mM Tris-HCl at pH 7.2, 10 mM MgCl 2 and 1 mM DTT) with His-PP1 or the indicated extracts. Aliquots were retrieved, washed with PBS plus NaCl (300 mM) and Triton X-100 (0.1%), eluted by SDS sample buffer and subjected to SDS-PAGE. Phosphorylation was detected by PhosphorImager (Molecular Dynamics).
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Figure S1 Ros (0.28mM) was added to CSF extract that had been pre-treated with DMSO or OA (10μM). Aliquots were withdrawn at the indicated times to immunoblot for Cdc27 and to measure Cdc2 kinase activity using Histone H1 (HH1) as an exogenous substrate. www.nature.com/naturecellbiology Figure S4B 
